FDA
EMA
MHRA
PMDA
Health Canada

Phase I
Phase II
Phase III
Readouts
Enrollment Signals

Pipeline Tracking
Company Moves
Asset Intelligence
Landscape Reports

Markets

Pricing
Access
Commercial
Launch Tracking

M&A Watch

Licensing
Acquisitions
Partnerships
Capital Raises

Strategy Catalysts Pricing

Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Company

Pricing
Partner with us
Subscribe
Contact
Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

Intelligence powered by the Humanexa engine.

Indication

Hodgkin Lymphoma

Clinical and regulatory intelligence for Hodgkin Lymphoma with 3 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 3
Catalysts: 0
Assets: 3

Relevant assets

Brentuximab →

Magrolimab →

Nivolumab →

Relevant companies

No related entities indexed yet.

Recent signals(3)

ClinicalAugust 21, 2026

Phase III Trial of Brentuximab Vedotin and Nivolumab in Hodgkin Lymphoma

A phase III trial is comparing the efficacy of adding brentuximab vedotin and nivolumab to standard chemotherapy in patients with stage I and II classical Hodgkin lymphoma, led by the National Cancer Institute.

ClinicalJuly 13, 2026

Brentuximab vedotin shows effectiveness over standard chemotherapy in relapsed Hodgkin lymphoma

A multicenter cohort study evaluates the real-world effectiveness and safety of brentuximab vedotin compared to standard chemotherapy in relapsed or refractory Hodgkin lymphoma.

ClinicalJuly 6, 2026

Magrolimab and Pembrolizumab Combination Study in Hodgkin Lymphoma Initiated

A clinical trial is underway to evaluate the safety and efficacy of magrolimab combined with pembrolizumab in relapsed or refractory classic Hodgkin lymphoma.

Upcoming catalysts

No catalysts indexed for this entity yet.

Therapeutic areas

Hodgkin Lymphoma →

Oncology →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.